N-terminal pro-brain natriuretic peptide as a prognostic predictor in critical care patients with acute cardiogenic pulmonary edema

Acta Cardiologica Sinica

Volumn 23, Issue 1, 2007, Pages 20-28

  Chuang, Chun Pin ^a   Lo, Huey Ming ^b,c   Wu, Chang Yu ^a   Jong, Yuh Shiun ^a   Ho, Feng Ming ^a,d  

^a TAO YUAN GENERAL HOSPITAL   (Taiwan)

^b SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d HSIN SHENG COLLEGE OF MEDICAL CARE AND MANAGEMENT   (Taiwan)

Author keywords

Acute heart failure; Acute pulmonary edema; Pro brain natriuretic peptid; Prognoses

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT; SPIRONOLACTONE; VASODILATOR AGENT;

ACUTE DISEASE; ADULT; AGED; ANEMIA; ARTICLE; BODY MASS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; KIDNEY DISEASE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; PROTEIN BLOOD LEVEL; SYSTOLIC HEART FAILURE;

EID: 34248681035     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001;344:17-22.
2. Bogaty P, Mure P, Dumesnil G. New insights into diastolic dysfunction as the cause of acute left-sided heart failure associated with systemic hypertension and/or coronary artery disease. Am J Cardiol 2002;89:341-5.
3. Smith GL, Masoudi FA, Vaccarino V, et al. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 2003; 41:1510-8.
4. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000;101:2118-21.
5. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 2003;339:321-8.
6. Wu AH, Smith A, Wieczorek S, et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003;92:628-31.
7. Maisel AS, Koon J, Krishnaswamy P, et al. Ultility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001;141:367-74.
8. Bay M, Kirk V, Parner J, et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 2003;89:150-4.
9. Keiko M, Takayoshi T, Atsuyuki W, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32.
10. Dokainish H, Zoghbi WA, Lakkis NM, et al. Optimal noninvasive assessment of left ventricular filling pressures: a comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation 2004; 109:2432-9.
11. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002;105:595-601.
12. Maisel AS, Krishnasway P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
13. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-54.
14. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-91.
15. Doust JA, Pietrzak E, Dobson A, et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005;330(7492):625.
16. Anand IS, Fisher LD, Chiang Y-T, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-83.
17. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-7.
18. Suzuki S, Yoshimura M, Nakayama M, et al. Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-term follow-up analysis. Circulation 2004;110:1387-91.
19. Kragelund C, Gronning B, Kober L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-75.
20. Kellett J. The prediction of in-hospital mortality by amino terminal pro-brain natriuretic peptide (NT-proBNP) levels and other independent variables in acutely ill patients with suspected heart disease. Eur J Intern Med 2005;16(3):195-9.
21. Chin BS, Chung NA, Gibbs CR, et al. Vascular endothelial growth factor and soluble P-selectin in acute and chronic congestive heart failure. Am J Cardiol 2002;90:1258-60.
22. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infraction: the Framingham Heart Study. Circulation 2003;107:1486-91.
23. Krauser DG, Lloyd-Jones DM, Chae CU, et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a proBNP Investigation of Dyspnea in Emergency Department (PRIDE) substudy. Am Heart J 2005;149.744-50.
24. Rivera M, Cortes R, Salvador A, et al. Obese subjects with heart failure have lower N-terminal pro-brain natriuretic peptide plasma levels irrespective of aetiology. Eur J Heart Failure 2005;7:1168-70.
25. Ralli S, Horwich TB, Fonarow GC. Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. Am Heart J 2005;150:1220-7.
26. Luchner A, Hengstenberg C, Lowel H, et al. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension 2005;46:118-23.
27. Valle R, Aspromonte N, Feola M, et al. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Cardiac Failure 2005; 11:498-503.
28. Johnson W, Omland T, Hall C, et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002; 39:1263-9.
29. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1587-93.
30. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
31. Knebel F, Schimke I, Pliet K, et al. NT-proBNP in acute heart failure: correlation with invasively measured hemodynamic parameters during recompensation. J Card Fail 2005;11(5 Suppl): S38-41.